MDMA (Ecstasy) alters how the body processes tramadol, a painkiller prone to abuse. In male rats, MDMA slowed tramadol absorption when given orally and increased tramadol concentrations when given intravenously. MDMA also inhibited the CYP3A4 enzyme, a key metabolizer of many drugs, suggesting broader drug interactions. For people who use both substances, intravenous tramadol may pose greater toxicity risks, while oral tramadol may require higher doses to achieve the same effect.
A single dose of MDMA (ecstasy) inhibits the liver enzyme CYP2D6, but the duration of inhibition depends on the concentration of the probe drug used to measure enzyme activity. Using a therapeutic concentration of dextromethorphan (2 µM), enzyme activity was significantly reduced only at 1 hour after MDMA, with recovery by 1 week. Using a saturated concentration (300 µM), activity was reduced at 1 hour, 1 week, and 1 month. The results suggest that the apparent recovery time of CYP2D6 after MDMA exposure varies with probe concentration, likely due to differences in metabolic pathways at different substrate levels.